Industries > Pharma > Pharma ADMET Testing Market 2017-2027

Pharma ADMET Testing Market 2017-2027

In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies

PUBLISHED: 28 June 2017
PAGES: 149
PRODUCT CODE: PHA0206

Clear
WOOCS 2.2.1

The pharma ADMET testing market is estimated at $7.43bn in 2016 and is expected to grow at a CAGR of 12.32% in the first half of the forecast period. The market is expected to grow at a CAGR of 10.50% in the second half of the forecast period. In 2016, the largest sector of the market was in vitro testing, which accounted for 44.3% of the ADMET testing market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 149-page report you will receive 100 charts– all unavailable elsewhere.

The 149-page report provides clear detailed insight into the pharma ADMET testing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Pharma ADMET Testing market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the main submarkets:
– In Vivo ADMET Testing
– In Vitro ADMET Testing
– In Silico ADMET Testing

Pharma ADMET Testing Market 2017-2027

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– The US
– Japan
– Germany
– France
– Italy
– Spain
– The UK
– China
– Brazil
– Russia
– India
– South Korea
– Rest of the World

• Our study includes SWOT and STEP analysis of this industry and market.

• Our study discusses the selected leading companies that are the major players in the ADMET Testing industry:
– Agilent Technologies
– BIOVIA
– Cyprotex
– Bio-Rad Laboratories
– Quintiles
– CMIC
– Charles River Laboratories
– WuXi PharmaTech
– Promega Corporation
– Sigma-Aldrich (part of Merck KGaA)

A company profile gives you the following information where available:
• Recent historical revenues
• Discussion of a company’s activities, technologies and outlook
• Brief assessment of the company’s ADMET strategy

Visiongain’s study is intended for anyone requiring commercial analyses for the pharma ADMET Testing market. You find data, trends and predictions.

Buy our report today Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharma ADMET Testing Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Pharma ADMET Testing Market 2017-2027


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category